FDA Classifies September Chlorthalidone Recall as Class II
The FDA has designated a September recall of certain chlorthalidone tablets by Inventia Healthcare as a Class II recall, citing failed dissolution specifications.
The U.S. Food and Drug Administration on September 17 classified a recall of chlorthalidone tablets initiated by Inventia Healthcare as a Class II recall. The recall follows a prior voluntary recall of other lots in June, which was also designated Class II. Chlorthalidone, a diuretic used to manage high blood pressure, is being recalled because the tablets failed to meet dissolution specifications, meaning the active ingredient may not dissolve properly for absorption.
A Class II recall indicates that the product may cause temporary or medically reversible health issues, though serious problems are considered unlikely. The September recall involves more than 13,000 bottles of 25 mg tablets, identified by batch number RISA24002 and an expiration date of April 2027. Patients are advised to check their medication labels for these details and to contact their pharmacist if they cannot verify the information.
"If you have the recalled medication, contact your healthcare provider right away and do not stop taking it without medical guidance," the advisory states.
The FDA notes that insufficient dissolution could reduce the drug’s effectiveness, but no additional details have been provided by Inventia Healthcare or the agency.